Citation for published version:
Sutherland, TE, Andersen, OA, Betou, M, Eggleston, IM, Maizels, RM, van Aalten, D & Allen, JE 2011, 'Analyzing airway inflammation with chemical biology: Dissection of acidic mammalian chitinase function with a selective drug-like inhibitor', Chemistry & Biology, vol. 18, no. 5, pp. 569-579.
https://doi.org/10.1016/j.chembiol.2011.02.017

DOI:
10.1016/j.chembiol.2011.02.017

Publication date:
2011

Document Version
Peer reviewed version

Link to publication

University of Bath

Alternative formats
If you require this document in an alternative format, please contact: openaccess@bath.ac.uk

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Analysing airway inflammation with chemical biology: dissection of acidic mammalian chitinase function with a selective drug-like inhibitor

Tara E Sutherland\textsuperscript{1}, Ole A Andersen\textsuperscript{2}, Marie Betou\textsuperscript{3}, Ian M Eggleston\textsuperscript{3}, Rick M Maizels\textsuperscript{1}, Daan van Aalten\textsuperscript{2}*, Judith E Allen\textsuperscript{1}*

1. Institute of Immunology and Infection Research, University of Edinburgh, Edinburgh EH9 3JT, Scotland, UK
2. Division of Molecular Microbiology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, UK
3. Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, England, UK

* These authors contributed equally to this work
* Joint corresponding authors

Running Title: Chemical dissection of AMCase function

Corresponding Authors:
Daan van Aalten (dmfvanaalten@dundee.ac.uk) & Judith E Allen (j.allen@ed.ac.uk)

Abbreviations: AMCase: Acidic mammalian chitinase, mAMCase: murine AMCase, hAMCase: human AMCase, CHIT1: chitotriosidase, Bis: bisdionin, BALF: bronchoalveolar lavage fluid, MMP: matrix-metalloprotease-, TIMP: tissue inhibitor of metalloproteinases
Summary

Acidic mammalian chitinase (AMCase) is produced in the lung during allergic inflammation and asthma and inhibition of enzymatic activity has been considered as a therapeutic strategy. However, most chitinase inhibitors are non-selective, additionally inhibiting chitotriosidase activity. Here we describe bisdionin F, a competitive AMCase inhibitor with 20-fold selectivity for AMCase over chitotriosidase, designed by utilising the AMCase crystal structure and dicaffeine scaffold. In a murine model of allergic inflammation, bisdionin F-treatment attenuated chitinase activity and alleviated the primary features of allergic inflammation including eosinophilia. However, selective AMCase inhibition by bisdionin F also caused dramatic and unexpected neutrophilia in the lungs. This class of inhibitor will be a powerful tool to dissect the functions of mammalian chitinases in disease and represents a synthetically accessible scaffold to optimize inhibitory properties in terms of airway inflammation.
INTRODUCTION

Chitin, the second most abundant polysaccharide in nature, is a principal component of the arthropod exoskeleton, nematode eggshell and fungal cell wall. Although mammals themselves do not synthesize chitin, they are continually exposed to this polymer through inhalation and exposure to chitin-containing pathogens. Chitin accumulation is limited through hydrolysis of β(1→4) glycosidic bonds by chitinases, members of the evolutionary conserved glycoside hydrolase family 18 (GH18). Mammals have two genes encoding active chitinases, chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase), that represent an ancient gene duplication event and show sequence homology to bacterial chitinases (Bussink, et al. 2007). More recent gene duplications have yielded the homologous chitinase-like proteins (CLPs), with mutations within the enzymatic machinery rendering the catalytic site inactive (Zaheer ul, et al. 2007). Although the functions of both chitinases and CLPs in mammals are still poorly understood, it is becoming clear that their expression is regulated in both innate and adaptive immune responses. CHIT1, which is expressed exclusively in phagocytes (Boot, et al. 2005), is thought to play an important role in the mammalian innate immune response against fungi, bacteria and other pathogens (Barone, et al. 2003; Labadaridis, et al. 2005). Conversely, increased production of AMCase and CLPs Ym1, Ym2, BRP-39 in rodents; and YKL-39 and YKL-40 in humans, is a prominent feature of Th2-driven pathologies, including infection, allergic inflammation and asthma (reviewed in (Sutherland, et al. 2009).
AMCase was first described to be expressed in the gastrointestinal tract and lungs of rodents and humans (Boot, et al. 2001). AMCase is expressed in tissue macrophages and epithelial cells, with its production driven by Th2-cytokines IL-4 and IL-13 (Zhu, et al. 2004). Early exploration of mammalian chitinase function implicated AMCase as a mediator of Th2-driven allergic airway diseases following the use of the chitinase inhibitor allosamidin, a pseudo-trisaccharide natural product derived from *Streptomyces* species (Sakuda 1986), in murine models (Zhu, et al. 2004). Treatment of allergen-challenged mice with allosamidin or demethylallosamidin significantly reduced eosinophilia, a hallmark of allergic inflammation (Matsumoto, et al. 2009; Zhu, et al. 2004). Although both compounds inhibit chitinase activity in vivo, only demethylallosamidin treatment reduces allergen or IL-13–induced airway hyper-responsiveness. Despite beneficial actions in models of Th2-driven allergic inflammation, the therapeutic potential of these compounds is limited due to their expensive and complex synthesis and commercial unavailability. In addition, allosamidin has a broad range of activity against all family 18 chitinases (Berecibar, et al. 1999), and possesses physicochemical properties that are not compatible with a drug-like compound, such as high molecular weight (604.7 Da), an undesirably low clogP (−4.7) and poor ligand efficiency (−0.25 kcal·mol⁻¹·atom⁻¹ for fungal chitinase) (Vaaje-Kolstad, et al. 2004). Allosamidin is a more effective inhibitor of CHIT1 than AMCase (IC⁵₀ murine CHIT1 [mCHIT1] ~50 nM and murine AMCase [mAMCase] ~400 nM) (Zheng, et al. 2005) (Boot, et al.)
This is of particular concern as CHIT1 is not an effector molecule in allergic inflammation and is rather regarded as a host-defense mechanism against chitin-containing pathogens (reviewed in Sutherland, et al. 2009). Thus, there is a need to identify compounds that are drug-like, selective inhibitors of AMCase that can be used in animal models to dissect the roles of the chitinases in allergic airway inflammation, and potentially further develop as anti-asthma therapies.

We recently identified xanthine derivatives as promising leads for GH18 inhibitors (Rao, et al. 2005) and subsequently developed a low micromolar chitinase inhibitor composed of two linked caffeine molecules (bisdionin) with desirable drug-like properties, a crystallographically defined binding mode and excellent synthetic accessibility (Schuttelkopf, et al. 2006). Here we describe the rational design of a novel AMCase inhibitor, bisdionin F, with 20-fold selectivity for AMCase over CHIT1 and demonstrate in vivo activity in a mouse model of acute allergic inflammation. Bisdionin F treatment in allergen-challenged mice reduced eosinophil recruitment and measurements of ventilatory function. Unexpectedly however, treatment with bisdionin F also resulted in neutrophilia and changes to expression of genes associated with remodelling. These studies highlight the complex mechanistic pathways surrounding the therapeutic inhibition of AMCase activity. Nonetheless, the potent selective activity of bisdionin F in vitro and in vivo and its relatively easy synthesis, makes this inhibitor an
invaluable tool for the chemical biological dissection of the roles of the different mammalian chitinases.
RESULTS

Rational design of bisdionin F, a hAMCase selective inhibitor

A recent report described the reduction of airway eosinophilia upon inhibition of total broncho-alveolar chitinase activity with the natural product chitinase inhibitor allosamidin (Zhu, et al. 2004). We recently described the bisdionins, dixanthine derivatives that are micromolar inhibitors of family 18 chitinases (Schuttelkopf, et al. 2006). A high-resolution crystal structure of bisdionin B (C2-dicaffeine) complexed with *Aspergillus fumigatus* chitinase B1 (*AfChiB1*) was solved and revealed the binding mode of bisdionin B (Schuttelkopf, et al. 2006). Whilst being less energetically favourable, the caffeine linker length of these molecules could be modified to alleviate strain and result in a more potent inhibitor (Schuttelkopf, et al. 2010). The most potent of these, bisdionin C (Fig. 1A), is a drug-like molecule as assessed by Lipinski’s rule of five: it has six hydrogen bond acceptors and no hydrogen bond donors, a molecular weight of 400.4 Da, a clogP of approximately 0 and a ligand efficiency of -0.41 kcal·mol⁻¹·atom⁻¹ against *AfChiB1* (Schuttelkopf, et al. 2010). We investigated whether bisdionin C would inhibit human AMCase (hAMCase) and/or human chitotriosidase (hCHIT1). Assessment of chitinase activity using a fluorescent substrate revealed that while bisdionin C inhibits hAMCase and hCHIT1 in the micromolar range, it does so with no apparent selectivity (Fig. 2).

To facilitate structure-guided optimisation of the bisdionin scaffold into a potent, selective hAMCase inhibitor, the crystal structure of the
hAMCase-bisdionin C complex was determined to 2.2 Å resolution (Table I, Fig. 1B). The native structure of hAMCase has recently been reported (Olland, et al. 2009), giving an RMSD of 0.80 Å with the structure reported here. The loops on the AMCase TIM barrel ([βα]₈ fold) produce a deep active site cleft similar to other “bacterial-type” family 18 chitinases. Bisdionin C spans the -1, -2 and -3 GlcNAc binding subsites of the AMCase chitooligosaccharide substrate (Fig. 1C). The methyl xanthine units bind at the bottom of the active site, stacking on the indole groups of Trp31 and Trp360 (Fig. 1C). The hydroxyl group of Tyr212 forms a hydrogen bond with N9, whereas the backbone N of Trp99 forms a hydrogen bond with O6. Water-mediated hydrogen bonds are formed between the carboxyl group of Asp213 and O2, and between the backbone oxygen and nitrogen atoms of Gly97 and Phe101, respectively, and bisdionin C O6’.

Although hCHIT1 and hAMCase catalytic domains share 57% sequence identity, there are two amino acids near the catalytic machinery that are different in hAMCase, His269 (Arg269 in hCHIT1) and Ile300 (Met300 in hCHIT1) (Fig. 1C). Interestingly, the N7 methyl group of bisdionin C appears to impose an unfavourable conformation of Asp138, a key catalytic residue that hydrogen bonds the catalytic acid (Glu140)/substrate N-acetyl group and stabilises the oxazolinium ion reaction intermediate during catalysis (Brameld, et al. 1998; Terwisscha van Scheltinga, et al. 1995; van Aalten, et al. 2001) (Fig. 1). Given the unfavourable interactions of the N7 methyl group and the non-conserved
amino acid substitutions on the opposite side of the xanthine moiety, we explored the effects of the N7 methyl group on potency and selectivity. We synthesised bisdionin F, the N7-demethylated derivative of bisdionin C (Fig. 1A). A 2.25 Å crystal structure of the hAMCase-bisdionin F complex reveal that Asp138 now adopts the "up" conformation, generating an additional hydrogen bond with the N7 of the xanthine in the -1 subsite, and also interacting with the catalytic acid (Glu140). The inhibitor bisdionin F was shown to further increase hAMCase inhibition by over one order of magnitude compared to bisdionin C, competitively inhibiting the enzyme with a $K_i = 420 \pm 10$ nM (Fig. 1B). The inhibitor shows this improved inhibition only towards hAMCase, not hCHIT1 ($IC_{50} = 17 \, \mu M$), thus introducing 20-fold selectivity (Fig 2A). It should be noted that hAMCase possesses a more negatively charged active site, generated by the Arg269 (hCHIT1) to His269 (hAMCase) substitution, also lowering of the pH optimum of the enzyme. Thus, electrostatic effects may explain why the imidazole moiety, generated by removing the methyl group, is better accommodated by the hAMCase enzyme.

**Bisdionin F reduces chitinase activity in a murine model of allergic inflammation.**

To verify that, as expected, bisdionin F would have similar activity against the mouse enzyme, recombinant mAMCase was stably expressed in COS-7 cells. After 10 min incubation, bisdionin F treatment resulted in a concentration- dependent inhibition of mAMCase activity with an $IC_{50}$ of $2.2 \pm 0.2 \, \mu M$ (Fig. 2B). To test the *in vivo* efficacy of bisdionin F,
a well-established model of airway lung inflammation was used, in which mice are first sensitized with ovalbumin (OVA) i.p. and then challenged in the airways, leading to increased chitinase activity in the lung tissue (Zhu, et al. 2004). Enzymatic activity in lung homogenates of mice treated with 5 mg/kg bisdionin F (Fig. 3A) was assessed in this model. As previously reported, chitinase activity significantly increases upon allergic challenge, as assayed approximately 24 hr after the last challenge while treatment with bisdionin F significantly reduced chitinase activity in the lungs of both control PBS and OVA-challenged mice.

**Bisdionin F modulates allergen-induced inflammation**

To assess the impact of AMCase inhibition on allergen-induced inflammation, cellular infiltrate into the bronchoalveolar lavage fluid (BALF) was examined on cytospins from vehicle and bisdionin F-treated animals (Fig. 3B and 3C). As expected, acute OVA-challenge induced a significant increase in eosinophils, lymphocytes and macrophages in the lavage fluid compared to PBS-challenged mice. Strikingly, bisdionin F-treated allergic mice were found to have significantly reduced total cell airway infiltrates (Fig. 3B, \( P < 0.01 \) compared to vehicle treatment), whereas cell numbers in PBS-challenged animals were not altered with chitinase inhibition. Differential counts of cells recovered from the BALF revealed a reduction in the number of lymphocytes and eosinophils following chitinase inhibition (Fig. 3C). However, the most unanticipated result of bisdionin F treatment was a 4-fold increase in
neutrophil cell number compared to vehicle-treated OVA-challenged mice (Fig. 3C).

Changes to inflammatory infiltrates were examined in haematoxylin and eosin stained lung sections (Fig. 3D and 3E). PBS-challenged mice had similar lung structure and cellular composition, whether treated with bisdionin F or vehicle (Fig. 3D, i and ii). Allergen challenge resulted in inflammatory cell influx into the lamina propria, perivascular and peribronchiolar regions of the lung. Following treatment with bisdionin F in allergic animals, inflammatory influx into the lung tissue was more striking (Fig. 3D and 3E). Staining with naphthol AS-D chloroacetate esterase, a stain specific for neutrophil granulocytes, revealed predominant neutrophil influx in bisdionin F OVA-challenged mice (Fig. 3F), consistent with the analysis of the BALF (Fig 3C).

To investigate the cause of the bisdionin F-induced neutrophilic response, cytokine and chemokine secretion from OVA-specific tLN cell cultures were examined with Luminex multiplex bead array. Potent neutrophil chemotactic factors KC (murine IL-8 equivalent) and IL-17 were not significantly altered in tLN cultures from chitinase inhibitor treated allergic mice (data not shown). However, both the secretion and expression of chemokine macrophage inhibitory protein-1 alpha (MIP-1α), also a neutrophil chemoattractant, were enhanced by bisdionin F treatment in OVA-challenged animals (Fig. 3G and 3H). MIP-1α levels
were not altered by OVA-challenge alone, correlating with a lack of significant neutrophil recruitment in these mice (Fig. 3C).

Altered eosinophil recruitment following bisdionin F treatment is dose-dependent

At a dose of 5 mg/kg, bisdionin F decreased eosinophil cell number and increased neutrophil cell number resulting in an unfavourable cell recruitment profile for the treatment of allergy. Thus, we investigated whether a lower dose of bisdionin F would allow effects on neutrophil and eosinophil cell numbers to be segregated. 1 mg/kg was the lowest dose at which we could observe any chitinase inhibition and thus allergic animals were treated with 1 and 5 mg/kg of bisdionin F and eosinophil and neutrophil recruitment was assessed (Fig. 4A). Increases in eosinophilia of OVA-challenged mice were reduced by treatment with both 1 and 5 mg/kg dose. However, at both doses, bisdionin F treatment also resulted in a significant 2-4-fold increase in neutrophil cell number. A bronchoconstrictor, methacholine, was administered following challenge with OVA or PBS, and penH (enhanced pause), a measurement that reflects changes to ventilatory function in spontaneously breathing mice, as described in detail in the experimental procedures. As expected penH was significantly increased in vehicle-treated allergic animals compared to naïve animals (P<0.001, Fig. 4C). A dose of 5 mg/kg bisdionin F had no effect on penH measurements in PBS-challenged animals (results not shown). However, bisdionin F treatment
significantly reduced penH in allergic mice at both 1 and 5 mg/kg at the highest concentration of methacholine used.

**Expression of genes associated with tissue remodelling are altered by chitinase inhibition**

It has been suggested that chitinases play a role in tissue remodelling responses in models of infection and Th2-driven inflammation (reviewed in (Lee 2009) with eosinophils also implicated in remodelling. We thus predicted that chitinase inhibition, leading to reduced eosinophilia, might have beneficial effects on the expression of genes associated with lung remodelling. Contrary to our expectation, the expression of genes associated with remodelling including procollagen I, matrix-metalloprotease-12 (MMP-12), and Ym1 (chitinase-like protein) were significantly increased in bisdionin F treated animals, while the tissue inhibitor of metalloproteinases 1 (TIMP-1) was down-regulated (Fig. 5A-D). Furthermore, the ratio of MMP:TIMP expression was enhanced 2.5 fold following bisdionin F treatment, suggesting enhanced MMP activity is likely (Fig. 5E).
DISCUSSION

The therapeutic targeting of chitinase enzymatic activity was proposed when it was discovered that AMCase is highly expressed in both animal models of allergic inflammation and in human asthmatics (Bierbaum, et al. 2005; Zhu, et al. 2004) and that non-specific inhibition of chitinases had anti-inflammatory effects (Matsumoto, et al. 2009; Zhu, et al. 2004). However, the inhibitors used in these studies are not specific for AMCase and do not provide tangible starting points for the development of such compounds. With the aid of hAMCase structural data, we undertook the design of a selective hAMCase inhibitor that would allow us to more precisely dissect the role of AMCase in allergic inflammation.

The design strategy for the novel chitinase inhibitor bisdionin F demonstrates that selective inhibitors of AMCase activity can be synthesised and as shown here, used in vivo to examine the function of AMCase during Th2-driven allergic inflammation. Importantly, our findings suggest that key properties of AMCase may have been overlooked using broad chitinase inhibitors.

Bisdionin F showed micromolar affinity against recombinant mAMCase in vitro and reduced both the increased lung chitinase enzymatic activity induced by allergic OVA challenge and the basal level of chitinase activity in naïve mice. Treatment with bisdionin F significantly reduced eosinophil cell numbers in the lavage of allergic mice, an effect that has been previously described for other chitinase inhibitors (Matsumoto, et al. 2009; Zhu, et al. 2004). Although the central role of eosinophils in
the allergic reaction is sometimes debated, reduced eosinophil numbers are associated with improvements in ventilatory function and tissue remodelling (Flood-Page, et al. 2003; Humbles, et al. 2004). In this current study, chitinase inhibition decreased penH in allergic animals at doses in which eosinophil recruitment was reduced by approximately 50%, supporting the notion that eosinophils regulate ventilatory function.

The most striking and consistent feature of bisdionin F treatment was the neutrophil recruitment observed in OVA-challenged mice but not control PBS-challenged mice. Whilst not considered a classical inflammatory mediator in Th2-driven allergy, neutrophils have increasingly and controversially been placed in the spotlight as important mediators of persistent and corticosteroid-resistant asthma (Green, et al. 2002; Jatakanon, et al. 1999). Recent studies have correlated chronic asthma severity with the numbers of neutrophils in the sputum and bronchial biopsies (Louis, et al. 2000; Woodruff, et al. 2001), with neutrophil recruitment and activation mediated largely by IL-8 (Monteseirin 2009). Bisdionin F-induced neutrophilia was accompanied by an increase in MIP-1α secretion and expression, both at the site of inflammation and the draining lymph nodes. Although the role of MIP-1α during allergic asthma has been described to a lesser extent than IL-8, the levels of MIP-1α are increased in lavage fluid from allergic asthmatics (Alam, et al. 1996) and hence may be an important component for induction of neutrophil chemotaxis. In addition to increased neutrophil numbers following bisdionin F treatment, we
observed alterations in airway remodelling genes that would be predicted to have negative consequences for lung function. Whether these changes were the result of the altered eosinophil/neutrophil balance or a more direct effect of the inhibitor remains to be determined.

Treatment with demethylallosamidin did not result in neutrophil recruitment in allergic mice (Matsumoto, et al. 2009), whilst the effects of allosamidin and anti-AMCase sera on neutrophil cell number were not reported (Zhu, et al. 2004). Bisdionin F-induced neutrophilia does correlate well with the inhibition of chitinase activity. Furthermore, in previous work the potential side effects of xanthine based (bisdionin) chitinase inhibitors were explored by monitoring phosphodiesterase inhibition, a known target of xanthine derivatives (Rao, et al. 2005). Results showed that as larger substituents were added to the N1 position of the xanthine structure, selectivity for the chitinases increased. Bisdionin F is further extended at this position, reducing the likelihood of off-target effects, although these cannot be fully excluded. Bisdionin F-induced neutrophilia could be mediated, at least in part, through chitin accumulation in the lungs. Chitin has been shown to induce inflammatory cell recruitment (Reese, et al. 2007), including neutrophils (Da Silva, et al. 2008). Whilst these immunological actions of chitin would normally be limited in mammals by chitinase mediated chitin degradation, interference with chitinase enzymatic activity would likely result in chitin accumulation. Because bisdionin F exhibits selectivity for
AMCase, unlike allosamidin, which is more effective at inhibiting CHIT1 (Boot, et al. 2001; Zheng, et al. 2005), the activity of CHIT1 in the lung should remain largely unaffected. Both CHIT1 and AMCase may be required to ensure full degradation and clearance of chitin. The level of chitinase activity in the lung and the predominance of one enzyme over the other may influence the size and quantity of chitin degradation products, which has been shown to determine the inflammatory outcome (Da Silva, et al. 2008). Importantly, if the ability of AMCase to break down chitin is important, the absence of neutrophils in PBS-challenged mice treated with bisdionin F suggests that other factors are at play and that an actively primed immune environment is required for chitin to induce neutrophilia.

In addition to inhibiting chitinase activity (Matsumoto, et al. 2009; Zhu, et al. 2004), AMCase has been targeted by RNA interference (Yang, et al. 2009) and anti-AMCase-sera (Zhu, et al. 2004). The overlap of all three treatments appears to be a reduction in eosinophilia, also observed with bisdionin F. Approaches that more specifically targeted AMCase, yielded additional effects not seen with broad chitinase inhibitors, including reduction of IL-13-induced chemotactic factors, antigen-specific IgE responses and airway hyper-responsiveness. Also consistent with our study, the RNA interference led to a small increase in neutrophils in animals infected with an adenoviral expressing short hairpin RNA (shRNA) against AMCase relative to mice which received a shRNA control (Yang, et al. 2009). Both anti-AMCase and shRNA treatment are likely to have
influenced protein levels and thus will not solely have addressed the role of AMCase enzymatic activity.

These studies along with the findings presented here, emphasize the importance of generating specific tools for dissecting the role of chitinases during Th2-driven allergic inflammation. A recent study has developed high-throughput, fragment and virtual based screening methods to identify a selective inhibitor of AMCase activity (Cole, et al. 2010). The study demonstrated inhibition of chitinase activity in vivo, albeit, at a much greater dosing regime (50 mg/kg twice daily) compared to bisdionin F but did not investigate the immunological or physiological consequences. We have used both structural and enzyme inhibition data to successfully design bisdionin F, and utilised this compound in vivo to selectively inhibit AMCase chitinolytic activity during allergic airway inflammation. Whilst our study has raised important questions regarding the therapeutic benefit of chitinase inhibition for the treatment of Th2-driven inflammatory conditions, bisdionin F is a valuable tool for understanding the yet unknown functions of AMCase. Further, studies in which the active site Asp138 has been mutated to Ala have demonstrated distinct enzyme-dependent and -independent properties for AMCase which can both be blocked by allosamidin (Hartl, et al. 2009). Thus, development of therapeutically useful inhibitors may still be possible, based on further refinement of the bisdionins in conjunction with a better understanding of both the chitinases and CLPs, some of which, like mutant AMCase, can still bind
chitin (and thus presumably chitinase inhibitors) but cannot cleave it (Hartl, et al. 2009; Mohanty, et al. 2009).

The active chitinases are highly conserved across mammals, while the CLPs represent more recent gene duplication events with subsequent loss-of-function mutations (Bussink, et al. 2007). This has resulted in an intriguing situation in which all mammals express the highly conserved active enzymes chitotriosidase and AMCase but additionally express a broad range of diverse CLPs without known function. The data presented herein have already demonstrated novel inhibitory effects of AMCase on neutrophil recruitment potentially through MIP-1α signalling. Intriguingly, following the direct transfection of Ym1 (a murine CLP), into the lungs of naïve mice we have observed neutrophil recruitment and enhanced MIP-1α secretion (unpublished observations). Thus enhanced Ym1 expression following bisdionin F treatment (Fig. 6A) may explain the increases in MIP-1α and neutrophilia. This raises the exciting possibility that chitinases and CLPs have cross-regulatory properties. Further, the dissection of the differential roles of this expanded gene family may lead to future combination therapies in which both eosinophilia and neutrophilia can be repressed for the successful treatment of allergies.

Although mouse CLPs cannot fully represent the human proteins, the evolutionary principles driving the remarkably rapid divergence of CLPs are likely to be shared across species. Thus studies in mice should allow
us to address fundamental functional differences between chitinases and CLPs. Indeed, the potential capacity of broad chitinase inhibitors such as allosamidin to bind a range of CLPs may have previously obscured AMCase-specific activities. It is only through the use of selective chemical tools like the bisdionins that we can begin to unravel the complex mechanistic and regulatory pathways of chitinase and CLP functions.
SIGNIFICANCE -

Chitotriosidase (CHIT1) and acidic mammalian chitinase (AMCase) are mammalian chitinases found in the lung and are upregulated during innate and adaptive immune responses, respectively. AMCase has previously been identified as a mediator in allergic inflammation and asthma, although most information regarding AMCase function has been provided through studies using allosamidin, a non-specific inhibitor of family 18 chitinases. To address the role of AMCase during Th2-driven inflammation, we used a rational approach to design a selective inhibitor of AMCase chitinase activity, bisdionin F. Bisdionin F showed in vivo efficacy in a murine model of allergic inflammation, and similar to allosamidin, attenuated lung chitinase activity, reduced eosinophil influx and improved ventilatory function. However, our studies with bisdionin F reveal new functions of AMCase that have previously gone unreported, likely due to the unspecific nature of other chitinase inhibitors. Neutrophils, whilst not typically associated with a Th2-allergic response, were strikingly enhanced with AMCase inhibition. While such results question the therapeutic potential of bisdionin F monotherapy and indeed other chitinase inhibitors for Th2-inflammatory conditions, it does not preclude the possibility to design AMCase inhibitors with appropriate actions. For example, beneficial effects of allosamidin and bisdionin F may be due to actions that are independent of direct chitinase activity. This same class of inhibitor could potentially be developed with activity against chitinase-like proteins (CLPs) without affecting chitinase activity. Thus, an understanding of the actions of the
highly diverse CLP family, that are also upregulated during Th2-driven conditions, as well as enzyme-independent actions of AMCase, warrants urgent attention. Overall the approach of designing a specific class of inhibitor that shows selectivity for AMCase has provided an invaluable tool to begin dissecting the function of AMCase during pathology and has already alluded to the potential of cross-regulatory actions of the chitinase and CLP family members.
EXPERIMENTAL PROCEDURES

*Bisdionin Synthesis*

Bisdionin C (Itahara and Imamura 1994), with an alkyl linker of three methylene units was synthesised as previously described (Schuttelkopf, et al. 2010). Bisdionin F was prepared according to the method of Allwood et al (Allwood, et al. 2007) by the alkylation of 1-(3-bromopropyl)-3, 7-dimethyl-1H-purine-2,6(3H, 7H)-dione (Fischer, et al. 1999) with 7-(4-methoxybenzyl)-3-methyl-1H-purine-2,6(3H, 7H)-dione (Sakai, et al. 1992), followed by removal of the 4-methoxybenzyl group under acidic conditions (Sakai, et al. 1992). Compounds were characterised by ¹H and ¹³C NMR and HRMS and revealed no trace contamination by high molecular weight species such as LPS. Purity was >95% as judged by analytical HPLC.

*Protein expression, crystallisation and structure determination of hAMCase complexes.*

A fragment corresponding to hAMCase 22-398 (bp 64-1194) was ligated into the pPIC9 vector (Invitrogen) using the Xho I and Not I restriction sites. The enzyme was subsequently overexpressed as a secreted protein from the *Pichia pastoris* GS115 strain and purified using a combination of affinity chromatography and size-exclusion chromatography. Pure hAMCase was spin concentrated to 37 mg/ml in 25 mM HEPES pH 6.8, 250 mM NaCl. The protein was crystallised at 30°C from 75% saturated NaCl, 0.1 M HEPES pH 7.4, using the hanging drop method. Crystals grew to an approximate size of 200 x 100 x 50 μm. Crystals were cryo-protected in
50% saturated NaCl, 20% glycerol in 0.1 M HEPES pH 7.4 and subsequently flash frozen in liquid nitrogen. The binary complexes were formed by soaking crystals in reservoir solution containing saturated concentrations of bisdionin C (4 hrs) and bisdionin F (2 hrs) prior to cryo-protection.

Data for hAMCase were collected at ID14-EH1 at the European Synchrotron Radiation Facilities (ESRF) using a cryo-stream of cold nitrogen (110 K). Processing and scaling were done using the HKL suite of programs (Otwinowski and Minor 1997). Initial phases were obtained by molecular replacement using MOLREP (Vagin and Teplyakov 1997) with the crystal structure of hCHIT1 as a search model (PDB entry 1LG2; (Fusetti, et al. 2002)). Cross-validation (Kleywegt and Brunger 1996) was applied by excluding 1% of the reflections throughout the refinement procedure. Rigid body and simulated annealing followed by several rounds of combined refinement (energy minimization and $B$-factor refinement) using strict non-crystallographic symmetry were done using CNS (Brunger, et al. 1998). The graphical program O (Jones, et al. 1991) combined with density modification including density averaging from the CCP4 program suite (Collaborative Computational Project 1994) was used for manual adjustments of the structures, and water molecules were included as oxygen atoms after each round of combined refinement using appropriate criteria. Refmac5 (Murshudov, et al. 1997) was used in latter stages of refinement. hAMCase crystallised in space group $P2_12_12_1$, and the final models contain six monomers each consisting of 377 residues per protein monomer. The overall fold of the six monomers are similar, with r.m.s.d values (C$\alpha$ atoms) of 0.21 - 0.32 Å upon
superposition. In the interest of simplicity, the structures are discussed consistently using the first monomer in the coordinate files. Topologies for ligands were obtained using the PRODRG server (Schuttelkopf and van Aalten 2004) and ligands were included using unbiased \( F_0 - F_c \), \( \phi_{\text{calc}} \) electron density maps.

**Generation of AMCase expressing stable cell lines**

The full length-coding region of mAMCase was amplified using a lung cDNA template. The cDNA fragment was directionally cloned into pcDNA3.1 (Invitrogen), to generate a V5/His tagged plasmid. TOP10 competent cells were transformed with the AMCase plasmid and sequence confirmed. Mammalian COS-7 cells were transfected with AMCase-pcDNA3.1 plasmid using Lipofectamine 2000 (Invitrogen). COS-7 cell supernatants were screened for AMCase protein by Western Blot and chitinase activity. A stable AMCase expressing cell line was generated using G418 selection medium (RPMI).

**Chitinase activity assay**

Chitinase activity of hAMCase, lung homogenates or AMCase COS-7 cell supernatants (serum-free) were determined using 4-methylumbelliferyl-\( \beta\)-d-\( N,N',N''\)-triacetylchitotrioside and 4-methylumbelliferyl-\( \beta\)-d-\( N,N',N''\)-triacetylchitobioside as described. Samples were incubated with substrate (0.022 mM in 100 mM citric acid, 200 mM sodium phosphate buffer, pH 5.2) in a final volume of 50 \( \mu \)L. After a 10 min incubation at 37°C, the reaction was stopped with the addition of 500 \( \mu \)L sodium
carbonate buffer (0.5 M sodium carbonate and 0.5 M sodium bicarbonate pH 10.6). Liberated 4-methlyumberlliferone was quantified using a microplate fluorometer (excitation 360 nm/emission 440 nm). $K_i$ and $IC_{50}$ values were determined in the presence of different concentrations of inhibitor. Experiments were performed in duplicate or triplicate.

**OVA sensitization and challenge**

All experiments used female BALB/c mice, 6-8 weeks old. Mice were kept in individually ventilated cages and all experiments were conducted under UK Home Office guidelines. Mice were sensitized (day 0) and boosted (day 14) i.p. with 20 $\mu$g OVA (Grade V, Sigma) adsorbed to 9% potassium alum. Mice were either challenged on day 28 and 30 with 50 $\mu$g OVA or PBS by the intratracheal route, or were challenged with 1% OVA or PBS by aerosol for 30 min on day 28 to day 30. Bisdionin F or vehicle (2% DMSO in PBS) was administered i.p., 2hrs prior to each challenge at doses indicated in the text. Necropsies were performed 24 hrs after the final airway challenge.

**Ventilatory Function**

On day 30, prior to the final OVA challenge and bisdionin F dose, ventilatory function (enhanced pause (penH)) was measured using unrestrained whole-body plethysmography (Buxco Systems) and analyzed with system XA software (Buxco Electronics) as previously described (Hamelmann, et al. 1997). Briefly, Conscious mice were placed in
individual chambers for a 10 min acclimatisation period. Spontaneous breathing patterns in mice relate to changes in chamber air pressure, which are measured by a transducer attached to the chamber wall. Differences in the rates of pressure change during peak inspiration and peak expiration and the timing of expiration are used to calculate penH according to the following equation; penH = ((expiratory time/relaxation time) - 1) x (peak expiratory flow (mL/s)/peak inspiratory flow (ml/s)). PenH measurements are not used as a quantitative measurement that relates to airway size and rather reflect changes to ventilation following bronchoconstriction. Baseline measurements of penH were made following an aerosol of PBS. Doubling doses of methacholine (3.125→50 mg/mL in PBS, Sigma) were aerosolized for 2 min followed by 5 min data collection. PenH measurements were averaged for the entire dose period.

**Bronchoalveolar Lavage**

Approximately 24 hrs after the last challenge, mice were killed, the trachea cannulated and internal airspaces lavaged with 400 μL of 0.25% BSA in PBS followed by three 300 μL washes. Total cell numbers were counted and cytospins prepared for differential cell counts which were assessed by morphology following Diff Quick staining (Reagena). BALF was centrifuged at 1200 g and supernatant stored at -20°C for further analysis.
**Lung protein homogenates**

Protein from dissected lung was homogenised (TissueLyser, Qiagen) in lysis buffer containing protease cocktail inhibitor (Sigma). Samples were incubated for 20 min on ice, prior to centrifugation 10,000 g to removed cell debris. Protein amounts were quantified with Coomassie (Bradford) Reagent. Homogenates were stored at -70°C for use in the chitinase activity assay.

**Histology**

Following BAL, the right lobe of the lung was fix-perfused with 4% formaldehyde and subsequently processed to paraffin and embedded. Standard H&E staining was performed to gross pathology and lung neutrophils were visualised by naphthol AS-D chloroacetate esterase staining (Sigma).

**RNA extraction and quantitative real-time PCR**

One part of the left lobe of the lung, removed following BALF, was stored in RNAlater (Ambion) at 4°C for up to 4 weeks. Lung samples were homogenized in RLT lysis buffer using TissueLyser (Qiagen) and total RNA extracted using RNeasy mini spin columns (Qiagen). 1 μg of RNA was used for synthesis of cDNA using Moloney murine leukemia virus reverse transcriptase. Relative quantification of genes was carried out by RT-PCR using the Roche Lightcycler, as previously described (Nair, et al. 2005). PCR amplification was analysed using 2nd derivative Maximum alogarithm (LightCycler 480 SW 1.5, Roche) and the expression of the
gene of interest was normalised to the housekeeping gene, GAPDH.

Primer sequences used were as follows: GAPDH- For 
ATGACATCAAGAAGGTGGTG, Rev CATACCAGAAATGAGCTTG; Ym1- For 
TCACAGGTCTGGCAATTCTTCTG, Rev TTGTCTTTAGGAGGGCTTCC; Pro 
Collagen I- For - AACTGGACTGTCCCAACCCC, Rev 
TCCCTGACTCCTACATTTCTTG; CCL3- For TGCCCTTGCTTCTCTCTC, 
Rev GTGGAATCTTCCGGCTGTAG; MMP-12- For 
CAATTGGAATATGACCCTCTGT, Rev AGCAAGCACCCTTCCA; and 
TIMP-1- For GTGGGAAATGCCGCAGAT, Rev GGGCATATCCACAGAGGCTTT.

**Cytokine and chemokine secretion from draining lymph node cell cultures**

The draining thoracic lymph nodes (tLN) were dissected and single cell suspensions made before being plated out at 1x10^6 cells/mL in 96-well plates (RPMI 1640 supplemented with L-glutamine, penicillin streptomycin and FCS). Cells were stimulated with 500 μg/mL OVA and incubated for 72 hrs at 37°C, 5% CO₂. MIP-1α levels were measured in cell-free supernatants using a Luminex kit (Invitrogen) and samples were read with a Luminex 100 multiplex bead array system.

**Statistical analysis**

Data are expressed as the mean ± standard error of the mean, with individual numbers indicated for each experiment. Statistical analysis was performed with PRISM 4.0 (Graphpad Software). Differences
between groups were determined using a one-way ANOVA with Dunnetts post-hoc test. A $P<0.05$ was considered a significant difference.
Acknowledgements

We would like to thank S. Duncan (University of Edinburgh) for her technical assistance with the murine model of allergic inflammation and S. Jenkins and D. Rückerl for helpful discussions. This work was supported by Asthma UK, the Medical Research Council UK and the Wellcome Trust.

Competing Financial Interests

The authors declare no competing financial interests.
REFERENCES

Alam, R., York, J., Boyars, M., Stafford, S., Grant, J.A., Lee, J., Forsythe, P., Sim, T., and Ida, N. (1996). Increased MCP-1, RANTES, and MIP-1alpha in bronchoalveolar lavage fluid of allergic asthmatic patients. Am J Respir Crit Care Med 153, 1398-1404.

Allwood, M.B., Cannan, B., van Aalten, D.M., and Eggleston, I.M. (2007). Efficient synthesis of 1,3,7-substituted xanthines by a safety-catch protection strategy. Tetrahedron 63, 12294-12302.

Barone, R., Simpore, J., Malaguarnera, L., Pignatelli, S., and Musumeci, S. (2003). Plasma chitotriosidase activity in acute Plasmodium falciparum malaria. Clin Chim Acta 331, 79-85.

Berecibar, A., Grandjean, C., and Siriwardena, A. (1999). Synthesis and Biological Activity of Natural Aminocyclopentitol Glycosidase Inhibitors: Mannostatins, Trehazolin, Allosamidins, and Their Analogues. Chem Rev 99, 779-844.

Bierbaum, S., Nickel, R., Koch, A., Lau, S., Deichmann, K.A., Wahn, U., Superti-Furga, A., and Heinzmann, A. (2005). Polymorphisms and haplotypes of acid mammalian chitinase are associated with bronchial asthma. Am J Respir Crit Care Med 172, 1505-1509.

Boot, R.G., Blommaart, E.F., Swart, E., Ghauharali-van der Vlugt, K., Bijl, N., Moe, C., Place, A., and Aerts, J.M. (2001). Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J Biol Chem 276, 6770-6778.

Boot, R.G., Bussink, A.P., Verhoek, M., de Boer, P.A., Moorman, A.F., and Aerts, J.M. (2005). Marked differences in tissue-specific expression of chitinases in mouse and man. J Histochem Cytochem 53, 1283-1292.

Brameld, K.A., Shrader, W.D., Imperiali, B., and Goddard, W.A., 3rd (1998). Substrate assistance in the mechanism of family 18 chitinases: theoretical studies of potential intermediates and inhibitors. J Mol Biol 280, 913-923.

Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. (1998). Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54, 905-921.

Bussink, A.P., Speijer, D., Aerts, J.M., and Boot, R.G. (2007). Evolution of Mammalian chitinase(-like) members of family 18 glycosyl hydrolases. Genetics 177, 959-970.

Cole, D.C., Olland, A.M., Jacob, J., Brooks, J., Bursavich, M.G., Czerwinski, R., DeClercq, C., Johnson, M., Joseph-McCarthy, D., Ellingboe, J.W., et al. (2010). Identification and characterization of acidic mammalian chitinase inhibitors. J Med Chem 53, 6122-6128.

Collaborative Computational Project, N. (1994). The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50, 760-763.

Da Silva, C.A., Hartl, D., Liu, W., Lee, C.G., and Elias, J.A. (2008). TLR-2 and IL-17A in chitin-induced macrophage activation and acute inflammation. J Immunol 181, 4279-4286.
Fischer, B., Yefidoff, R., Major, D.T., Rutman-Halili, I., Shneyvays, V., Zinman, T., Jacobson, K.A., and Shainberg, A. (1999). Characterization of “mini-nucleotides” as P2X receptor agonists in rat cardiomyocyte cultures. An integrated synthetic, biochemical, and theoretical study. J Med Chem 42, 2685-2696.

Flood-Page, P.T., Menzies-Gow, A.N., Kay, A.B., and Robinson, D.S. (2003). Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167, 199-204.

Fusetti, F., von Moeller, H., Houston, D., Rozeboom, H.J., Dijkstra, B.W., Boot, R.G., Aerts, J.M., and van Aalten, D.M. (2002). Structure of human chitotriosidase. Implications for specific inhibitor design and function of mammalian chitinase-like lectins. J Biol Chem 277, 25537-25544.

Green, R.H., Brightling, C.E., Woltmann, G., Parker, D., Wardlaw, A.J., and Pavord, I.D. (2002). Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57, 875-879.

Hamelmann, E., Schwarze, J., Takeda, K., Oshima, A., Larsen, G.L., Irvin, C.G., and Gelfand, E.W. (1997). Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 156, 766-775.

Hartl, D., He, C.H., Koller, B., Da Silva, C.A., Kobayashi, Y., Lee, C.G., Flavell, R.A., and Elias, J.A. (2009). Acidic mammalian chitinase regulates epithelial cell apoptosis via a chitinolytic-independent mechanism. J Immunol 182, 5098-5106.

Humbles, A.A., Lloyd, C.M., McMillan, S.J., Friend, D.S., Xanthou, G., McKenna, E.E., Ghiran, S., Gerard, N.P., Yu, C., Orkin, S.H., et al. (2004). A critical role for eosinophils in allergic airways remodeling. Science 305, 1776-1779.

Itahara, T., and Imamura, K. (1994). Preparation and NMR Study of 7,7"-(a,ω-Alkanediyl)bis[theophylline], 1,1"-(a,ω-Alkanediyl)bis[theobromine], and 1,1"-(a,ω-Alkanediyl)bis[3-methyluracil]. Bulletin of the Chemical Society of Japan 67, 7.

Jatakanon, A., Uasuf, C., Maziak, W., Lim, S., Chung, K.F., and Barnes, P.J. (1999). Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 160, 1532-1539.

Jones, T.A., Zou, J.Y., Cowan, S.W., and Kjeldgaard, M. (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47 ( Pt 2), 110-119.

Kleywegt, G.J., and Brunger, A.T. (1996). Checking your imagination: applications of the free R value. Structure 4, 897-904.

Labadaridis, I., Dimitriou, E., Theodorakis, M., Kafalidis, G., Velegaki, A., and Michelakakis, H. (2005). Chitotriosidase in neonates with fungal and bacterial infections. Arch Dis Child Fetal Neonatal Ed 90, F531-532.

Lee, C.G. (2009). Chitin, chitinases and chitinase-like proteins in allergic inflammation and tissue remodeling. Yonsei Med J 50, 22-30.
Louis, R., Lau, L.C., Bron, A.O., Roldaan, A.C., Radermecker, M., and Djukanovic, R. (2000). The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 161, 9-16.

Matsumoto, T., Inoue, H., Sato, Y., Kita, Y., Nakano, T., Noda, N., Eguchi-Tsuda, M., Moriwaki, A., Kan, O.K., Matsumoto, K., et al. (2009). Demethylallosamidin, a chitinase inhibitor, suppresses airway inflammation and hyperresponsiveness. Biochem Biophys Res Commun 390, 103-108.

Mohanty, A.K., Fisher, A.J., Yu, Z., Pradeep, M.A., Janjanam, J., and Kaushik, J.K. (2009). Cloning, expression, characterization and crystallization of BRP39, a signalling glycoprotein expressed during mammary gland apoptosis. Protein Expr Purif 64, 213-218.

Monteseirin, J. (2009). Neutrophils and asthma. J Investig Allergol Clin Immunol 19, 340-354.

Murshudov, G.N., Vagin, A.A., and Dodson, E.J. (1997). Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240-255.

Nair, M.G., Gallagher, I.J., Taylor, M.D., Loke, P., Coulson, P.S., Wilson, R.A., Maizels, R.M., and Allen, J.E. (2005). Chitinase and Fizz family members are a generalized feature of nematode infection with selective upregulation of Ym1 and Fizz1 by antigen-presenting cells. Infect Immun 73, 385-394.

Olland, A.M., Strand, J., Presman, E., Czerwinski, R., Joseph-McCarthy, D., Krykbaev, R., Schlingmann, G., Chopra, R., Lin, L., Fleming, M., et al. (2009). Triad of polar residues implicated in pH specificity of acidic mammalian chitinase. Protein Sci 18, 569-578.

Otwinowski, Z., and Minor, W. (1997). Processing of X-ray Diffraction Data Collected in Oscillation Mode. Methods in Enzymology 276, 307-326.

Rao, F.V., Andersen, O.A., Vora, K.A., Demartino, J.A., and van Aalten, D.M. (2005). Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes. Chem Biol 12, 973-980.

Reese, T.A., Liang, H.E., Tager, A.M., Luster, A.D., Van Rooijen, N., Voehringer, D., and Locksley, R.M. (2007). Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature 447, 92-96.

Sakai, R., Konno, K., Yamamoto, Y., Sanae, F., Takagi, K., Hasegawa, T., Iwasaki, N., Kakiuchi, M., Kato, H., and Miyamoto, K. (1992). Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem 35, 4039-4044.

Sakuda, S., Isogai, A., Matsumoto, S., Suzuki, A., and Koseki, K. (1986). The structure of allosamidin, a novel insect chitinase inhibitor produced by Streptomyces sp. Tetrahedron Letters 27, 2475-2478.

Schuttelkopf, A.W., Andersen, O.A., Rao, F.V., Allwood, A., Rush, C., Eggleston, I.M., and van Aalten, D.M. (2010). Bisdionin C - a rationally designed, nanomolar inhibitor of family 18 chitinases. ACS Med Chem Lett In press.
Schuttelkopf, A.W., Andersen, O.A., Rao, F.V., Allwood, M., Lloyd, C., Eggleston, I.M., and van Aalten, D.M. (2006). Screening-based discovery and structural dissection of a novel family 18 chitinase inhibitor. J Biol Chem 281, 27278-27285.

Schuttelkopf, A.W., and van Aalten, D.M. (2004). PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60, 1355-1363.

Sutherland, T.E., Maizels, R.M., and Allen, J.E. (2009). Chitinases and chitinase-like proteins: potential therapeutic targets for the treatment of T-helper type 2 allergies. Clin Exp Allergy 39, 943-955.

Terwisscha van Scheltinga, A.C., Armand, S., Kalk, K.H., Isogai, A., Henrissat, B., and Dijkstra, B.W. (1995). Stereochemistry of chitin hydrolysis by a plant chitinase/lysozyme and X-ray structure of a complex with allosamidin: evidence for substrate assisted catalysis. Biochemistry 34, 15619-15623.

Vaaje-Kolstad, G., Houston, D.R., Rao, F.V., Peter, M.G., Synstad, B., van Aalten, D.M., and Eijsink, V.G. (2004). Structure of the D142N mutant of the family 18 chitinase ChiB from Serratia marcescens and its complex with allosamidin. Biochim Biophys Acta 1696, 103-111.

Vagin, A.A., and Teplyakov, A. (1997). MOLREP: an automated program for molecular replacement. J. Appl. Cryst. 30, 1022-1025.

van Aalten, D.M., Komander, D., Synstad, B., Gaseidnes, S., Peter, M.G., and Eijsink, V.G. (2001). Structural insights into the catalytic mechanism of a family 18 exo-chitinase. Proc Natl Acad Sci U S A 98, 8979-8984.

Woodruff, P.G., Khashayar, R., Lazarus, S.C., Janson, S., Avila, P., Boushey, H.A., Segal, M., and Fahy, J.V. (2001). Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 108, 753-758.

Yang, C.J., Liu, Y.K., Liu, C.L., Shen, C.N., Kuo, M.L., Su, C.C., Tseng, C.P., Yen, T.C., and Shen, C.R. (2009). Inhibition of Acidic Mammalian Chitinase by RNA Interference Suppresses Ovalbumin-Sensitized Allergic Asthma. Hum Gene Ther.

Zaheer ul, H., Dalal, P., Aronson, N.N., Jr., and Madura, J.D. (2007). Family 18 chitolectins: comparison of MGP40 and HUMGP39. Biochem Biophys Res Commun 359, 221-226.

Zheng, T., Rabach, M., Chen, N.Y., Rabach, L., Hu, X., Elias, J.A., and Zhu, Z. (2005). Molecular cloning and functional characterization of mouse chitotriosidase. Gene 357, 37-46.

Zhu, Z., Zheng, T., Homer, R.J., Kim, Y.K., Chen, N.Y., Cohn, L., Hamid, Q., and Elias, J.A. (2004). Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 304, 1678-1682.
Figure Legends

**Figure 1:** (A) Chemical structures and atom numbering of bisdionin C and bisdionin F are shown with the differing methyl/hydrogen moieties highlighted in red. (B) Lineweaver-Burk plot showing bisdionin F inhibition of hAMCase at different concentrations. The data are compatible with a competitive inhibition model, giving a $K_i$ of 420 ± 10 nM. (C) Stereo figures of the active sites (monomer A) of the hAMCase-bisdionin C (top) and hAMCase-bisdionin F (bottom) complexes. Unbiased Fo-Fc $\varphi_c$ electron density maps are contoured at 2.5$\sigma$. Protein side chains, glycerol and ligand molecules are shown as a stick models with grey, yellow and magenta C atoms, respectively. hAMCase residues not conserved compared to CHIT1 are shown with orange C atoms. Water molecules interacting with the ligand are shown as orange spheres and hydrogen-bonding interactions are shown as dotted green lines. The second, less defined, ligand molecules stacking against Trp99 and Trp218 are omitted for clarity. N-acetyl glucosamine residues taken from the HCGP-39 in complex with chitin (PDB ID 1HJW) and Asp138 in the “up-conformation” are shown as stick models with transparent green C atoms.
**Figure 2:** (A) IC$_{50}$ values ($K_i$ values are shown in parenthesis) of bisdionin C and F compounds against hAMCase and hCHIT1. All values are given in μM. (B) Bisdionin F inhibits recombinant mAMCase enzymatic activity *in vitro.* Chitinase activity was determined using a fluorescent 4-methylumbelliferyl (4-MU) substrate. An AMCase expressing COS-7 cell-free supernatant was used as a source of enzymatically active recombinant mAMCase. rAMCase, in the presence of 4-MU substrate, was incubated with DMSO vehicle or increasing concentrations of bisdionin F for 10 min at 37°C. Chitinase activity is measured relative to the amount of substrate hydrolysed/hr/mL sample. IC$_{50}$ = 2.21 ± 0.18 μM.

**Figure 3:** Inhibition of allergen-induced lung chitinase activity and changes to cell recruitment in lavage and lung tissue. (A) Chitinase activity measured in lung homogenates from PBS/OVA-challenged mice treated with vehicle or bisdionin F. Bisdionin F reduced chitinase activity (expressed as 4MU substrate hydrolysed/hour/mg of lung tissue) in both PBS-challenged and OVA-challenged mice. (B) Total cell number and (C) differential cell counts, of macrophages, lymphocytes, neutrophils and eosinophils in bronchoalveolar lavage from bisdionin F and vehicle treated PBS and OVA-challenged mice. (D) Representative H&E stained lung sections (i) Vehicle PBS-challenged mice, (ii) bisdionin F PBS-challenged mice, (iii) vehicle OVA-challenged mice and (iv) bisdionin F OVA-challenged mice. Magnification x400. (E) Representative H&E...
stained lung sections from a second independent experiment; (i) vehicle OVA-challenged mice and (ii) bisdionin F OVA-challenged mice. Magnification x200. (F) Representative lung sections stained with naphthol AS-D choloracetate esterase showing (i) vehicle OVA-challenged mice or (ii) bisdionin F OVA-challenged mice. Neutrophils exhibit red staining, cell nuclei stained with haematoxylin. Magnification x400. (G) Protein levels of MIP-1α in supernatant of tLN cells from PBS or OVA-challenged mice, cultured in RPMI or OVA antigen (0.5 mg/mL) for 72 hrs. (H) Expression of MIP-1α mRNA from lung of PBS and OVA-challenged mice, normalised to the level of housekeeping gene, GAPH, in individual lung samples. Chitinase inhibitor, bisdionin F, 5 mg/kg i.p., n=5-7 per group. NS, not significant, * P<0.05, **P<0.01 and ***P<0.001 compared to vehicle PBS; #P<0.01, ##P<0.01, ###P<0.001. Data is representative of 3 individual experiments.

**Figure 4:** Treatment with two different doses of bisdionin F during allergic inflammation. (A) Eosinophil and neutrophil cell numbers in the bronchoalveolar lavage from chitinase inhibitor treated allergic mice compared to vehicle treatment. (B) Chitinase activity, measured in lung homogenates from OVA-challenged mice treated. (C) Relationship of chitinase inhibition on ventilatory function in allergic animals. PenH values were measured in conscious, unrestrained mice administered with increasing doses of aerosolised bronchoconstrictor, methacholine. Vehicle-treated PBS-challenged mice, open squares; Vehicle-treated OVA-challenged mice, closed squares; 1 mg/kg bisdionin F OVA-
challenged, open circles; 5 mg/kg bisdionin F closed circles, dashed line. Chitinase inhibitor, bisdionin F 1 and 5 mg/kg, i.p.; n=5-6 mice per group. NS not significant, **P<0.01 and ***P<0.001 compared to vehicle PBS and #P<0.05 and ##P<0.01 compared to vehicle OVA-challenged mice.

Figure 5: Chitinase inhibition alters the expression of genes involved implicated in lung tissue remodelling. mRNA expression of (A) Ym1, (B) pro-collagen I, (C) TIMP-1 and (D) MMP-12 were measured in RNA extracted from lung tissue of PBS-challenged animals or vehicle and bisdionin F -treated allergic animals. (E) The ratio of MMP-12:TIMP-1 mRNA expression. Chitinase inhibitor, bisdionin F, 1 and 5 mg/kg i.p.; n=5-6 mice per group. *P<0.05, **P<0.01, ***P<0.001 compared to vehicle PBS-challenged mice; #P<0.05 and ###P<0.001 compared to vehicle OVA-challenged mice.
Table 1: Summary of data collection and structure refinement statistics for the hAMCase-bisdionin C and F complexes. Values for the highest resolution shell are shown in parenthesis.

|                           | hAMCase + bisdionin C | hAMCase + bisdionin F |
|---------------------------|-----------------------|-----------------------|
| Resolution (Å)            | 20-2.20 (2.25-2.20)   | 20-2.25 (2.33-2.25)   |
| Cell dimensions (Å)       | 145.21 149.07 152.08  | 144.78 149.19 151.28  |
| Number of unique reflections | 161985               | 154470               |
| Multiplicity              | 4.3                   | 4.1                   |
| Rmerge (%)                | 10.1 (69.6)           | 9.6 (57.7)           |
| I/σ(I)                    | 14.1 (2.7)            | 14.8 (2.7)           |
| Completeness (%)          | 99.9 (99.9)           | 99.6 (99.8)           |
| Number of atoms in refinement | 19339               | 19347               |
| Number of solvent molecules | 1057              | 1119               |
| Rwork (%)                 | 18.1                  | 17.3                 |
| Rfree (%)                 | 22.8                  | 21.9                 |
| Average protein B-factor (Å²) | 31.3                 | 28.5                 |
| Average ligand B-factor (Å²) *¹ | 42.0             | 22.6                 |
| Average solvent B-factor (Å²) | 31.5                 | 29.7                 |
| r.m.s.d. bond lengths (Å) | 0.022                 | 0.023                |
| r.m.s.d. bond angels (º)  | 1.86                  | 1.89                 |
| Ramachandran plot statistics (%) |       |       |
|---------------------------------|-------|-------|
| Residues in favoured regions    | 97.7  | 98.0  |
| Residues in allowed regions     | 2.1   | 2.0   |
| Residues in outlier regions     | 0.1   | 0.0   |

*1 calculated from ligand molecules occupying the -1 and -3 subsites.
### Table A

| Inhibitor     | hAMCase    | hCHIT1     |
|---------------|------------|------------|
| Bisdionin C   | 20 ± 1 μM  | 8.3 ± 0.7 μM |
| Bisdionin F   | 0.92 ± 0.04 μM (0.42 ± 0.01 μM) | 17.1 ± 1 μM |

### Graph B

**AMCase Activity**

(4MU/hr/mL)

![Graph showing AMCase activity against log [Inhibitor]](image)
A B
Chitinase activity (nmol 4MU/hr/mg lung)

Total cell number (x10^5)

C D
Macrophage cell number (x10^5)

Eosinophil cell number (x10^5)

Neutrophil cell number (x10^5)

Lymphocyte cell number (x10^5)

G H
MIP-1α pg/mL

MIP-1α/GAPDH

Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
PBS OVA PBS OVA PBS OVA PBS OVA

Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor Vehicle Inhibitor
A

Eosinophil cell number (x10^5)

|        | Veh (PBS) | Veh (OVA) | 1mg/kg | 5mg/kg |
|--------|-----------|-----------|--------|--------|
| **     | 8         | 8         | 7      | 6      |
| ***    | **        | **        | **     | **     |

Neutrophil cell number (x10^5)

|        | Veh (PBS) | Veh (OVA) | 1mg/kg | 5mg/kg |
|--------|-----------|-----------|--------|--------|
|        | 3         | 5         | 2      | 7      |
| NS     | #         | #         | #      | #      |

B

Chitinase activity (nmol 4MU/hr/mg lung)

|       | Vehicle (PBS) | Vehicle (OVA) | 1mg/kg | 5mg/kg |
|-------|---------------|---------------|--------|--------|
| **    | 275           | 250           | 225    | 200    |
| **    | **            | **            | **     | **     |

C

PenH

| [MeCh] mg/mL | 0 | 10 | 20 | 30 | 40 | 50 |
|-------------|---|----|----|----|----|----|
| Vehicle (PBS) | 0 |    |    |    |    |    |
| Vehicle (OVA) | 0 |    |    |    |    |    |
| 1mg/kg       | 0 |    |    |    |    |    |
| 5mg/kg       | 0 |    |    |    |    |    |

**Significance:

*** p < 0.001
** p < 0.01
# p < 0.05
NS = Not Significant
